(NASDAQ: CRDL) Cardiol Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.58%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.75%.
Cardiol Therapeutics's revenue in 2024 is $0.On average, 2 Wall Street analysts forecast CRDL's revenue for 2027 to be $2,173,616,800, with the lowest CRDL revenue forecast at $1,578,257,538, and the highest CRDL revenue forecast at $2,768,976,061. On average, 2 Wall Street analysts forecast CRDL's revenue for 2028 to be $6,871,465,375, with the lowest CRDL revenue forecast at $5,097,477,762, and the highest CRDL revenue forecast at $8,645,452,989.
In 2029, CRDL is forecast to generate $15,151,272,363 in revenue, with the lowest revenue forecast at $15,151,272,363 and the highest revenue forecast at $15,151,272,363.